Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"
Date Insider Type Main position Quantity % Market Cap.
20-10-12
Nestle Health Science SA (Private Equity)
BuyCompany 54,117,287 82.6848%
20-10-12Others

Director

109,372 0.1671%
20-10-09Tender

General Counsel

391,686 0.5984%
Change 5-day change 1-year change 3-year change Capi.($)
-0.29%+0.20% - - 2.27B
+0.60%+5.95%+71.85%+120.48% 56.65B
+4.00%+7.51%+63.67%+68.77% 47.49B
-0.77%-0.67%-15.34%-15.95% 22.81B
+2.93%+1.17%-3.97%+384.78% 21.37B
+1.30%+3.73%+27.10%-17.51% 16.12B
+1.84%+8.52%+24.80%-35.50% 15.56B
-1.08%-3.11%+27.20%+158.30% 12.91B
+3.30%+15.02%+133.24%+273.89% 12.86B
+1.43%-6.44%+21.49% - 11.67B
Average +1.45%+2.16%+38.89%+117.16% 24.16B
Weighted average by Cap. +1.78%+3.27%+45.06%+110.23%
Logo Aimmune Therapeutics, Inc.
Aimmune Therapeutics, Inc. is a biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company's therapeutic approach, Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens. PALFORZIA is its internally developed product utilizing CODIT. PALFORZIA is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis, that occurs with accidental exposure to peanut. PALFORZIA is to be used in conjunction with a peanut-avoidant diet. Its subsidiaries include Aimmune Therapeutics UK Limited, Aimmune Therapeutics (Bermuda) Ltd., Aimmune Therapeutics Netherlands Cooperatief U.A., Aimmune Therapeutics Netherlands B.V., Aimmune Therapeutics Ireland Limited and Aimmune Therapeutics Germany GmbH.
Employees
-
  1. Stock Market
  2. Stocks
  3. AIMT Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!